Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.

Six new medicines for conditions including cancer and liver disease will be made available for NHS Scotland patients.

Ionis has also secured European Union approval for WAINZUA, a treatment for hereditary transthyretin-mediated amyloidosis, following positive Phase 3 trial results. Additionally, a partnership with ...

Ionis Pharmaceuticals, Inc. announced that Ionis and AstraZeneca’s Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis ...

Drug discovery firm Exscientia has claimed a world first after announcing that the first precision engineered drug generated by artificial intelligence (AI) is entering clinical trials. UK-based ...

WAINZUA was approved under the brand name WAINUA for the treatment of ATTRv-PN in the U.S. in December 2023 and has gained approvals in additional countries worldwide.

CARLSBAD, Calif. - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.37 billion market cap biotechnology company, has received approval from the European Union for its treatment WAINZUA, intended for ...

CARLSBAD, Calif. - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.37 billion market cap biotechnology company, has received approval from the European Union for its treatment WAINZUA, intended ...

WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.